NASDAQ · NTRB
Nutriband Inc.
$6.64+$0.24 (+3.75%)
Nutriband Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.75% below the high.
Loading market information…
NASDAQ · TLPH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Talphera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Talphera, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Talphera, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 31, 2025 |
| -$0.07+66.67% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$0.13+35.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $3.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.64+$0.24 (+3.75%)
Nutriband Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.75% below the high.
$0.81+$0.01 (+1.17%)
iBio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
$0.28+$0.03 (+11.45%)
Cosmos Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
$3.86-$0.09 (-2.28%)
SCYNEXIS, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.68% below the high.
$0.57+$0.02 (+2.79%)
MIRA Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.34% below the high.
$0.58-$0.01 (-1.15%)
Retractable Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.67% below the high.
$4.20+$0.17 (+4.22%)
P3 Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.13% below the high.
$3.34-$0.04 (-1.09%)
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
